JPH08507067A - Hiv逆転写酵素阻害剤 - Google Patents

Hiv逆転写酵素阻害剤

Info

Publication number
JPH08507067A
JPH08507067A JP6519119A JP51911994A JPH08507067A JP H08507067 A JPH08507067 A JP H08507067A JP 6519119 A JP6519119 A JP 6519119A JP 51911994 A JP51911994 A JP 51911994A JP H08507067 A JPH08507067 A JP H08507067A
Authority
JP
Japan
Prior art keywords
substituted
alkyl
chloro
carboxamide
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP6519119A
Other languages
English (en)
Japanese (ja)
Inventor
ウイリアムス,テレサ・エム
シツカローネ,テレンス・エム
サアリ,ウオルフレツド・エス
ウエイ,ジヨン・エス
グリーンリー,ウイリアム・ジエイ
バラーニ,スレツシユ・ケイ
ゴールドマン,マーク・イー
ホフマン,ヤコブ・エム・ジユニア
ルマ,ウイリアム・シー・ジユニア
ハフ,ジヨエル・アール
ルーネイ,クラレンス・エス
サンダーソン,フイリツプ・イー
テオハリデス,アンソニー・デイー
Original Assignee
メルク エンド カンパニー インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク エンド カンパニー インコーポレーテッド filed Critical メルク エンド カンパニー インコーポレーテッド
Publication of JPH08507067A publication Critical patent/JPH08507067A/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
JP6519119A 1993-02-24 1994-02-15 Hiv逆転写酵素阻害剤 Pending JPH08507067A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2192593A 1993-02-24 1993-02-24
US021,925 1993-02-24
PCT/US1994/001694 WO1994019321A1 (en) 1993-02-24 1994-02-15 Inhibitors of hiv reverse transcriptase

Publications (1)

Publication Number Publication Date
JPH08507067A true JPH08507067A (ja) 1996-07-30

Family

ID=21806886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP6519119A Pending JPH08507067A (ja) 1993-02-24 1994-02-15 Hiv逆転写酵素阻害剤

Country Status (13)

Country Link
EP (1) EP0686148A4 (zh)
JP (1) JPH08507067A (zh)
KR (1) KR960701010A (zh)
CN (1) CN1119856A (zh)
AU (1) AU6254294A (zh)
BG (1) BG62089B1 (zh)
BR (1) BR9405737A (zh)
CA (1) CA2156420A1 (zh)
FI (1) FI953954A0 (zh)
HU (1) HUT74614A (zh)
NO (1) NO953308L (zh)
PL (1) PL175788B1 (zh)
WO (1) WO1994019321A1 (zh)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536362A (ja) * 1999-02-05 2002-10-29 アストラゼネカ アクチボラグ 抗炎症剤としてのインドール誘導体
JP2007513950A (ja) * 2003-12-11 2007-05-31 アベンティス・ファーマスーティカルズ・インコーポレイテツド カゼインキナーゼIεの阻害剤としての置換1H−ピロロ[3,2−b,3,2−c,及び2,3−c]ピリジン−2−カルボキシアミド及び関連類似物
JP2009221205A (ja) * 2002-08-09 2009-10-01 Merck & Co Inc チロシンキナーゼ阻害薬
JP2009235072A (ja) * 2002-08-09 2009-10-15 Merck & Co Inc チロシンキナーゼ阻害薬
JP2010504978A (ja) * 2006-09-29 2010-02-18 アイデニクス ファーマシューティカルズ,インコーポレーテッド Hiv阻害剤としての鏡像異性的に純粋なホスホインドール
JP2011513234A (ja) * 2008-02-22 2011-04-28 アイアールエム・リミテッド・ライアビリティ・カンパニー Gpr119活性モジュレーターとしての化合物および組成物
JP2013525490A (ja) * 2010-05-06 2013-06-20 メルク・シャープ・エンド・ドーム・コーポレイション Faahのモジュレータとして有用なアザインドール誘導体

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989263B1 (en) * 1994-09-23 2006-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein
US5811425A (en) * 1997-03-04 1998-09-22 Abbott Laboratories Heterocyclic compounds as COX-2 inhibitors
AU7962200A (en) * 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
EP1390029B1 (en) * 2001-04-11 2009-12-16 Idenix (Cayman) Limited Phenylindoles for the treatment of hiv
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) * 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
EP1545510A4 (en) * 2002-08-07 2006-11-15 Idenix Cayman Ltd SUBSTITUTED PHENYLINDOLE FOR THE TREATMENT OF HIV
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
ATE445396T1 (de) 2004-08-19 2009-10-15 Aventis Pharma Inc 3-arylthioindol-2-carbonsäureamidderivate und ihre analoge als hemmer von caseinkinase i
DE602005023360D1 (de) 2004-09-17 2010-10-14 Idenix Pharmaceuticals Inc Phosphoindole als HIV-Inhibitoren
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
CN101454284A (zh) 2006-05-26 2009-06-10 阿斯利康(瑞典)有限公司 联芳基或芳基-杂芳基取代的吲哚类化合物
CN106892854B (zh) * 2015-12-21 2019-04-30 中国海洋大学 一种吲哚生物碱类化合物及其制备方法和用途
CN107151223B (zh) * 2016-03-10 2020-03-31 中国医学科学院药物研究所 一类n-烷基吲哚类化合物在制备抗流感病毒药物中的用途
CN106995400B (zh) * 2017-04-10 2019-08-06 湘潭大学 一种化合物及其盐及其合成方法
CN112375027B (zh) * 2020-12-07 2023-03-31 中国药科大学 吲哚磺酰胺类衍生物及其医药用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1935671C3 (de) * 1968-04-26 1975-01-09 Sumitomo Chemical Co 2-Aminomethylindole und ihre Salze
US4255442A (en) * 1977-08-29 1981-03-10 Schering Corporation 2-[(Methylsulfinyl)]-3-phenylindoles
IT1098266B (it) * 1977-08-29 1985-09-07 Scherico Ltd 2-sostituti-3-fenilindoli,procedimento per la loro preparazione e per il loro impiego come immunosoppresori
NZ222878A (en) * 1986-12-17 1991-02-26 Merck Frosst Canada Inc 3-hetero-substituted-n-benzyl-indole derivatives, and pharmaceutical compositions
CA1338012C (en) * 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
US5268389A (en) * 1989-10-16 1993-12-07 Uniroyal Chemical Company, Inc. Thiocarboxylate ester compounds compositions containing the same
CA2071529C (en) * 1989-12-28 2001-03-20 Donna Lee Romero Diaromatic substituted anti-aids compounds
WO1993005020A1 (en) * 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002536362A (ja) * 1999-02-05 2002-10-29 アストラゼネカ アクチボラグ 抗炎症剤としてのインドール誘導体
JP2009221205A (ja) * 2002-08-09 2009-10-01 Merck & Co Inc チロシンキナーゼ阻害薬
JP2009235072A (ja) * 2002-08-09 2009-10-15 Merck & Co Inc チロシンキナーゼ阻害薬
JP2007513950A (ja) * 2003-12-11 2007-05-31 アベンティス・ファーマスーティカルズ・インコーポレイテツド カゼインキナーゼIεの阻害剤としての置換1H−ピロロ[3,2−b,3,2−c,及び2,3−c]ピリジン−2−カルボキシアミド及び関連類似物
JP4691506B2 (ja) * 2003-12-11 2011-06-01 アベンティス・ファーマスーティカルズ・インコーポレイテツド カゼインキナーゼIεの阻害剤としての置換1H−ピロロ[3,2−b,3,2−c,及び2,3−c]ピリジン−2−カルボキシアミド及び関連類似物
JP2010504978A (ja) * 2006-09-29 2010-02-18 アイデニクス ファーマシューティカルズ,インコーポレーテッド Hiv阻害剤としての鏡像異性的に純粋なホスホインドール
JP2011513234A (ja) * 2008-02-22 2011-04-28 アイアールエム・リミテッド・ライアビリティ・カンパニー Gpr119活性モジュレーターとしての化合物および組成物
JP2013525490A (ja) * 2010-05-06 2013-06-20 メルク・シャープ・エンド・ドーム・コーポレイション Faahのモジュレータとして有用なアザインドール誘導体

Also Published As

Publication number Publication date
CN1119856A (zh) 1996-04-03
EP0686148A4 (en) 1996-02-07
HU9502468D0 (en) 1995-10-30
BR9405737A (pt) 1995-12-05
PL175788B1 (pl) 1999-02-26
PL310410A1 (en) 1995-12-11
NO953308L (no) 1995-10-24
HUT74614A (en) 1997-01-28
CA2156420A1 (en) 1994-09-01
FI953954A (fi) 1995-08-23
AU6254294A (en) 1994-09-14
KR960701010A (ko) 1996-02-24
WO1994019321A1 (en) 1994-09-01
EP0686148A1 (en) 1995-12-13
FI953954A0 (fi) 1995-08-23
BG99879A (bg) 1996-02-28
BG62089B1 (bg) 1999-02-26
NO953308D0 (no) 1995-08-23

Similar Documents

Publication Publication Date Title
JPH08507067A (ja) Hiv逆転写酵素阻害剤
US5527819A (en) Inhibitors of HIV reverse transcriptase
JP5487214B2 (ja) キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
JP6393830B2 (ja) ミクロソームプロスタグランジンe2シンターゼ−1を阻害するのに有用な新規メチルピペリジン化合物
TW520989B (en) Pharmaceutical composition for treating dementia, dementia of the Alzheimer's type, dyskinesias and behavioral manifestations of mental retardation, conduct disorder and autistic disorder
KR101605061B1 (ko) 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체
EP1599464B1 (fr) Derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2000509719A (ja) 置換されたアザビシクロ化合物、ならびにtnfおよびサイクリックampホスホジエステラーゼ産生の阻害剤としてのそれらの使用
CN107635404B (zh) 用于治疗疾病的mct4抑制剂
CA3010847A1 (en) Methods and compounds for restoring mutant p53 function
JPH05208910A (ja) Hiv逆転写酵素の阻害剤
JP2008508229A (ja) 複素環置換された環状尿素誘導体、その調製及びキナーゼ阻害剤としてのその薬学的使用
WO2001056607A1 (fr) Inhibiteurs de l'expression de l'integrine
JP2003525273A (ja) Pdeivを阻害するアミド、組成物および治療方法
FR2804114A1 (fr) Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
JP2001506230A (ja) 新規ピペラジン含有化合物
TW200800185A (en) Acid secretion inhibitor
JP2008266349A (ja) 3−ピリジル基を有する置換チアゾール誘導体、その製造法および用途
JP2009508872A (ja) カルバゾール誘導体
TW200922932A (en) Heterocyclic compound and pharmaceutical composition thereof
TW201217362A (en) Heteroaryls and uses thereof
JP7130873B2 (ja) バニン阻害剤としてのヘテロ芳香族化合物
JP5289769B2 (ja) 3−(インドリル)−4−アリールマレイミド誘導体および脈管形成阻害剤としてのそれらの使用
JP2008516903A (ja) 抗癌剤としての新規アザインドールチアゾリノン
JP3012338B2 (ja) アリールおよびヘテロアリールアルコキシナフタレン誘導体